Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 2Leukemia, B-Cell 2Leukemia 2Hematologic Diseases 2Bronchiolitis Obliterans Syndrome 2Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, B-Cell 1Lymphoma 1Immunoproliferative Disorders 1Immune System Diseases 1Blood Protein Disorders 1

Interventions

Bortezomib 4fludarabine 3Lenalidomide 3dacetuzumab 2Tacrolimus 2Dexamethasone 2Alemtuzumab 2plerixafor 1ofatumumab 1isatuximab 1fludarabine phosphate 1ficlatuzumab 1epratuzumab 1Whole-Body Irradiation 1Vorinostat 1Stem Cell Transplantation 1Rifaximin 1Mycophenolic Acid 1KW-2478 1Hsp90 inhibitor KU757 1Granulocyte Colony-Stimulating Factor 1Erlotinib Hydrochloride 1Cyclophosphamide 1Clonal Hematopoiesis 1Chromatin Immunoprecipitation Sequencing 1Calcium Dobesilate 1CLR1404 1Busulfan 1Blood Cell Count 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraproteinemias × KW-2478 × Lymphoid × Clear all
NCT01063907 2024-04-25

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Kyowa Kirin Co., Ltd.

Phase 1/2 Completed
95 enrolled 13 charts
LymphoidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Blood Protein Disorders, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias, Leukemia, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡